Pivotal Therapeutics (PVTTF) 0.0470 $PVTTF
Pivotal Therapeutics Announces Payment of Interest on Outstanding Convertible Notes
CNW Group - Thu Jun 18, 4:53PM CDT
Pivotal Therapeutics Inc. (OTCQX
VTTF; CSE VO), ("Pivotal" or the "Company"
, a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced that on June 17, 2015 it issued 780,722 common shares of the Corporation (the "Common Shares" . The Common Shares represented payment of interest for the period of March 5(th), 2015 to June 4(th), 2015 on its outstanding Convertible Notes that is due on or before July 1, 2015. Interest on the Notes, at the rate of 8% per annum, is payable quarterly in either cash or Common Shares, at the option of the Company. Common Shares issued in payment of interest are valued at the greater of CDN $0.20 per share and such price as may be allowed under the CSE Policy. The issued and outstanding number of shares now total 95,013,710.
First patient enrolled in Pivotal's POMEGA Phase IIa clinical trial with PVT-100
PR Newswire - Thu Jun 04, 1:25PM CDT
Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced today the enrollment of the first patient in Pivotal's POMEGA Phase IIa clinical trial with PVT-100.
Pivotal Therapeutics Announces First Quarter Financial Results
CNW Group - Mon Jun 01, 8:19PM CDT
Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced its operational highlights and financial results for the three months ended March 31, 2015. All dollar amounts referenced herein are in Canadian dollars unless otherwise stated.
Pivotal Therapeutics Inc. is to be Featured on CEO Clips on CBC's The Documentary Channel
CNW Group - Mon May 11, 2:17PM CDT
Pivotal Therapeutics Inc. (CSE VO; OTCQX VTTF), ("Pivotal" or the "Company" , a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced today the company and Mrs. Rachelle MacSweeney, Co-Founder, President and COO will be featured on CEO Clips on CBC's The Documentary Channel. CEO Clips, a series which profiles the most innovative publicly traded companies in North America, will feature Pivotal on The Documentary Channel beginning May 11, 2015, Monday through Friday, throughout the day and evenings. It can also be viewed online via this link: http://www.b-tv.com/pivotal-therapeutics-ceo-clip/.
Pivotal Therapeutics Announces 2014 Financial Results
CNW Group - Thu Apr 30, 8:20PM CDT
Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced its operational highlights and financial results for the fiscal year ended December 31, 2014. All dollar amounts referenced herein are in Canadian dollars unless otherwise stated.
Pivotal receives Health Canada approval to expand the indication of OMAZEN® to include products with claims to maintain and support cardiovascular health and normal triglyceride levels
CNW Group - Mon Apr 27, 11:48AM CDT
Pivotal Therapeutics Inc. (OTCQX VTTF; CSE VO), ("Pivotal" or the "Company" , a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced today that it received Health Canada approval to expand the indication of OMAZEN(®)'s product line specifically for cardiovascular health. The Natural and Non-Prescription Health Products Directorate of Health Canada (NNHPD) issued Natural Product Number (NPN) NPN 80060196 with the claim that helps to maintain and support cardiovascular health and NPN 80060197 with the claim helps to support and maintain normal serum/blood triglycerides/triacylglycerol levels. These new products contain the same unique formulation and high purity as OMAZEN(®) and will also be positioned for the professional market such as Wellness Clinics, Cardiac Rehabilitation Clinics, Sports Medicine Clinics and Private Executive Healthcare Clinics.
Pivotal executes Memorandum of Understanding for exclusive distribution of Benefishial(TM) line of products in Korea
CNW Group - Wed Apr 15, 8:10AM CDT
Pivotal Therapeutics Inc. (OTCQX VTTF; CSE VO), ("Pivotal" or the "Company" , a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced today that it has entered into a Memorandum of Understanding with Korea Animal Medical Science Institute (KAMSI) and its newly created affiliate for the exclusive sales and distribution of the BeneFishial(TM )family of products. The BeneFishial(TM )family of products consists of the following six products: (i) BeneFishial(TM) for overall health and well being, (ii) BeneFishial(TM )for cardiovascular health, (iii) BeneFishial(TM )for prenatal health, (iv) BeneFishial(TM )for toddler's health, (v) BeneFishial(TM )for child's health and (vi) BeneFishial(TM )for pet's health (veterinary application).
Pivotal executes Memorandum of Understanding for exclusive distribution of Benefishial™ line of products in Korea
PR Newswire - Wed Apr 15, 8:10AM CDT
Pivotal Therapeutics Inc. (OTCQX VTTF; CSE VO), ("Pivotal" or the "Company" , a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced today that it has entered into a Memorandum of Understanding with Korea Animal Medical Science Institute (KAMSI) and its newly created affiliate for the exclusive sales and distribution of the BeneFishial(TM) family of products. The BeneFishial(TM) family of products consists of the following six products: (i) BeneFishial(TM) for overall health and well being, (ii) BeneFishial(TM) for cardiovascular health, (iii) BeneFishial(TM) for prenatal health, (iv) BeneFishial(TM) for toddler's health, (v) BeneFishial(TM) for child's health and (vi) BeneFishial(TM) for pet's health (veterinary application).
Pivotal Therapeutics Announces Payment of Interest on Outstanding Convertible Notes
CNW Group - Thu Jun 18, 4:53PM CDT
Pivotal Therapeutics Inc. (OTCQX
VTTF; CSE VO), ("Pivotal" or the "Company" , a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced that on June 17, 2015 it issued 780,722 common shares of the Corporation (the "Common Shares" . The Common Shares represented payment of interest for the period of March 5(th), 2015 to June 4(th), 2015 on its outstanding Convertible Notes that is due on or before July 1, 2015. Interest on the Notes, at the rate of 8% per annum, is payable quarterly in either cash or Common Shares, at the option of the Company. Common Shares issued in payment of interest are valued at the greater of CDN $0.20 per share and such price as may be allowed under the CSE Policy. The issued and outstanding number of shares now total 95,013,710. First patient enrolled in Pivotal's POMEGA Phase IIa clinical trial with PVT-100
PR Newswire - Thu Jun 04, 1:25PM CDT
Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced today the enrollment of the first patient in Pivotal's POMEGA Phase IIa clinical trial with PVT-100.
Pivotal Therapeutics Announces First Quarter Financial Results
CNW Group - Mon Jun 01, 8:19PM CDT
Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced its operational highlights and financial results for the three months ended March 31, 2015. All dollar amounts referenced herein are in Canadian dollars unless otherwise stated.
Pivotal Therapeutics Inc. is to be Featured on CEO Clips on CBC's The Documentary Channel
CNW Group - Mon May 11, 2:17PM CDT
Pivotal Therapeutics Inc. (CSE
VO; OTCQX VTTF), ("Pivotal" or the "Company" , a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced today the company and Mrs. Rachelle MacSweeney, Co-Founder, President and COO will be featured on CEO Clips on CBC's The Documentary Channel. CEO Clips, a series which profiles the most innovative publicly traded companies in North America, will feature Pivotal on The Documentary Channel beginning May 11, 2015, Monday through Friday, throughout the day and evenings. It can also be viewed online via this link: http://www.b-tv.com/pivotal-therapeutics-ceo-clip/. Pivotal Therapeutics Announces 2014 Financial Results
CNW Group - Thu Apr 30, 8:20PM CDT
Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced its operational highlights and financial results for the fiscal year ended December 31, 2014. All dollar amounts referenced herein are in Canadian dollars unless otherwise stated.
Pivotal receives Health Canada approval to expand the indication of OMAZEN® to include products with claims to maintain and support cardiovascular health and normal triglyceride levels
CNW Group - Mon Apr 27, 11:48AM CDT
Pivotal Therapeutics Inc. (OTCQX
VTTF; CSE VO), ("Pivotal" or the "Company" , a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced today that it received Health Canada approval to expand the indication of OMAZEN(®)'s product line specifically for cardiovascular health. The Natural and Non-Prescription Health Products Directorate of Health Canada (NNHPD) issued Natural Product Number (NPN) NPN 80060196 with the claim that helps to maintain and support cardiovascular health and NPN 80060197 with the claim helps to support and maintain normal serum/blood triglycerides/triacylglycerol levels. These new products contain the same unique formulation and high purity as OMAZEN(®) and will also be positioned for the professional market such as Wellness Clinics, Cardiac Rehabilitation Clinics, Sports Medicine Clinics and Private Executive Healthcare Clinics. Pivotal executes Memorandum of Understanding for exclusive distribution of Benefishial(TM) line of products in Korea
CNW Group - Wed Apr 15, 8:10AM CDT
Pivotal Therapeutics Inc. (OTCQX
VTTF; CSE VO), ("Pivotal" or the "Company" , a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced today that it has entered into a Memorandum of Understanding with Korea Animal Medical Science Institute (KAMSI) and its newly created affiliate for the exclusive sales and distribution of the BeneFishial(TM )family of products. The BeneFishial(TM )family of products consists of the following six products: (i) BeneFishial(TM) for overall health and well being, (ii) BeneFishial(TM )for cardiovascular health, (iii) BeneFishial(TM )for prenatal health, (iv) BeneFishial(TM )for toddler's health, (v) BeneFishial(TM )for child's health and (vi) BeneFishial(TM )for pet's health (veterinary application). Pivotal executes Memorandum of Understanding for exclusive distribution of Benefishial™ line of products in Korea
PR Newswire - Wed Apr 15, 8:10AM CDT
Pivotal Therapeutics Inc. (OTCQX
VTTF; CSE VO), ("Pivotal" or the "Company" , a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced today that it has entered into a Memorandum of Understanding with Korea Animal Medical Science Institute (KAMSI) and its newly created affiliate for the exclusive sales and distribution of the BeneFishial(TM) family of products. The BeneFishial(TM) family of products consists of the following six products: (i) BeneFishial(TM) for overall health and well being, (ii) BeneFishial(TM) for cardiovascular health, (iii) BeneFishial(TM) for prenatal health, (iv) BeneFishial(TM) for toddler's health, (v) BeneFishial(TM) for child's health and (vi) BeneFishial(TM) for pet's health (veterinary application). 
